Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CGP 77116 in Multiple Sclerosis
NCT00001781Phase 2Completed
- Sponsor
- National Institute of Neurological Disorders and Stroke
- Start
- Feb 1998
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tiplimotide in multiple sclerosis (MS), sponsored by National Institute of Neurological Disorders and Stroke. Primary endpoints: Safety and Tolerability, Gadolinium-enhancing lesions on MRI and 1 more. Started Feb 1998; status: completed.
02
Drugs
tiplimotide
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT00001781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001781.